1. Show article details.

    BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

    Business Wire – 7:00 AM ET 10/20/2021

    This marks the first regulatory approval for BRUKINSA in Russia BRUKINSA is now approved for the treatment of MCL in ten countries, following the U.S., China, Canada, Australia, and others BeiGene (BGNE) is committed to rapidly advancing the global registration of BRUKINSA on its own and alongside strategic collaborators Under an exclusive distribution agreement, Nanolek will commercialize BRUKINSA in...

  2. Show article details.

    BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

    Business Wire – 5:00 PM ET 10/10/2021

    Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia To date, BRUKINSA is approved in mantle cell lymphoma in nine countries BeiGene (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, toda...

  3. Show article details.

    BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia

    Business Wire – 5:00 PM ET 10/10/2021

    Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia To date, BRUKINSA is approved in mantle cell lymphoma in nine countries BeiGene (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, toda...

  4. Show article details.

    BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia

    Business Wire – 4:06 PM ET 10/07/2021

    Represents BRUKINSA’s Second Recent Approval in the Asia-Pacific Region, Following October 1 Approval in Singapore for Treatment of Patients with Mantle Cell Lymphoma The TGA approval is based on results from ASPEN, an Australia-inclusive head-to-head clinical trial evaluating BRUKINSA compared to ibrutinib in patients with Waldenström’s macroglobulinemia CAMBRIDGE, Mass.

  5. Show article details.

    BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia

    Business Wire – 4:05 PM ET 10/07/2021

    Represents BRUKINSA’s second recent approval in the Asia-Pacific region, following October 1 approval in Singapore for treatment of patients with mantle cell lymphoma The TGA approval is based on results from ASPEN, an Australia-inclusive head-to-head clinical trial evaluating BRUKINSA compared to ibrutinib in patients with Waldenström’s macroglobulinemia SYDNEY & CAMBRIDGE, Mass.

  6. Show article details.

    BeiGene Announces Inclusion in FTSE Russell Indices

    Business Wire – 7:00 AM ET 09/20/2021

    BeiGene (BGNE) added to FTSE Global Equity Index Large Cap, All-World, All-Cap, Total-Cap; as well as the Developed ESG Low Carbon Select Index and Asia ex Japan ESG Low Carbon Select Index BeiGene (BGNE), Ltd., a global biotechnology company focused on developing and commercializing innovative medicines worldwide, has announced its inclusion in several FTSE Russell indices, including: the FTSE Global Equity...

  7. Show article details.

    BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

    Business Wire – 8:00 AM ET 09/17/2021

    BeiGene’s European commercial team is preparing to launch BRUKINSA, the company’s first medicine submitted for marketing authorization in the EU, upon approval The CHMP recommendation is based on results from the Phase 3 ASPEN trial, in which BRUKINSA demonstrated a numerically higher very good partial response rate and a favorable safety profile compared to ibrutinib BASEL, Switzerland & C...

  8. Show article details.

    U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

    Business Wire – 7:00 AM ET 09/15/2021

    This marks the third FDA approval for BRUKINSA and first approval in marginal zone lymphoma Twenty percent of patients achieved complete remission with single-agent BRUKINSA BRUKINSA was generally well-tolerated, consistent with its known safety profile CAMBRIDGE, Mass. This press release features multimedia. This accelerated approval is based on overall response rate.

  9. Show article details.

    BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma

    Business Wire – 12:00 AM ET 09/13/2021

    This marks the first ex-China regulatory filing for tislelizumab, following approval in five indications in China The accepted BLA, filed in collaboration with Novartis, is supported by the positive global Phase 3 RATIONALE 302 trial in patients with previously treated, advanced or metastatic ESCC and safety data from tislelizumab’s broad clinical program With its second internally developed ...

  10. Show article details.

    BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021

    Business Wire – 6:05 PM ET 09/12/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and subgroup analyses from the Company’s robust lung cancer program will be presented at the European Society for Medical Oncology Congress 2021.

  11. Show article details.

    U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

    Business Wire – 5:33 PM ET 09/01/2021

    This marks the second FDA approval for BRUKINSA and its third approval in Waldenström’s macroglobulinemia globally The approval is based on Phase 3 ASPEN trial comparing BRUKINSA against ibrutinib BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® has received approval from the U.S. Food and ...

  12. Show article details.

    BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal Cancer

    Business Wire – 7:00 PM ET 08/22/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental Biologics License Application for anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with ...

  13. Show article details.

    BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström’s Macroglobulinaemia

    Business Wire – 1:00 AM ET 08/18/2021

    BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Swissmedic has accepted the marketing authorization application for BRUKINSA, a treatment option for adult patients with Waldenström’s macroglobulinaemia . Swissmedic has started the formal review of the MAA.

  14. Show article details.

    BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma

    Business Wire – 9:23 AM ET 08/17/2021

    CAMBRIDGE, Mass. This press release features multimedia. “Dinutuximab beta represents an important biologic therapy for pediatric patients in China, having been listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA,” commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.

  15. Show article details.

    BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma

    Business Wire – 7:00 AM ET 08/17/2021

    CAMBRIDGE, Mass. “Dinutuximab beta represents an important biologic therapy for pediatric patients in China, having been listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA,” commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene.

  16. Show article details.

    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021

    Business Wire – 7:00 AM ET 08/16/2021

    BeiGene, Ltd. (BGNE), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company’s early development pipeline and research.

  17. Show article details.

    BeiGene Reports Second Quarter 2021 Financial Results

    Business Wire – 4:05 PM ET 08/05/2021

    CAMBRIDGE, Mass. “We continued executing on our key strategic objectives during the second quarter and took steps to further position BeiGene (BGNE) to become highly impactful to oncology patients worldwide,” said John V. Oyler, Co-Founder, Chairman and Chief Executive Officer of BeiGene.

  18. Show article details.

    BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey

    Business Wire – 7:00 AM ET 08/03/2021

    Company expects to recruit hundreds of new hires in the area to support clinical research, development, regulatory, pharmacovigilance, and manufacturing BeiGene, Ltd. (BGNE), a global biotechnology company focused on developing and commercializing innovative cancer medicines worldwide, announced today its plans to build a new campus for R&D and manufacturing at the Princeton West Innovation Campus in ...

  19. Show article details.

    Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

    GlobeNewswire – 8:30 AM ET 06/30/2021

    Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021.

Page:

Today's and Upcoming Events

  • Nov
    15

    BGNE to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    05

    BGNE announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.